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Th17 lymphocytes, that produce IL17A, IL17F, and IL22, play a crucial role during
the immune response against Mycobacterium tuberculosis (Mtb) infection. Whereas,
the contribution of IL17A in immunity to tuberculosis is usually accepted, the role of
IL17F has been scarcely studied so far. The aim of this work was to evaluate the
existence of a potential association of the non-synonymous variant rs763780 SNP of the
IL17F gene with human tuberculosis. Accordingly, by comparing healthy donors (HD)
and tuberculosis patients (TB) populations we demonstrated an association between
the C allele of the SNP and the susceptibility to tuberculosis disease in Argentina.
Furthermore, we found that peripheral blood mononuclear cells (PBMCs) from individuals
with a more effective immune response against Mtb secreted the highest levels of
IL17F when stimulated with a lysate of Mtb (Mtb-Ag). Besides, we evidenced that
Mtb-Ag-stimulated PBMCs from HD carrying the C variant of the SNP displayed the
lowest IFNG secretion, proliferation index, and SLAM expression as compared to TT
carriers. Moreover,Mtb-Ag-stimulated PBMCs from TB carrying the C allele produced the
lowest levels of IFNG, the highest level of IL17A, and the minimum proliferation indexes
as compared to TT TB, suggesting a relationship between the C allele and tuberculosis
severity. In fact, TB carrying the C allele presented amore severe disease, with the highest
bacilli burden in sputum. Together, our findings identify the IL17F rs763780 SNP as
a biomarker of tuberculosis susceptibility and advanced disease severity in Argentina,
suggesting that IL17F could be a critical cytokine in tuberculosis immunity.
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INTRODUCTION
Mycobacterium tuberculosis (Mtb) is the major cause of death by
a microbiological agent, causing nearly 1.6 million of deaths per
year. Moreover, Mtb infects almost 2 billon persons and causes
nearly 10 million of new cases of tuberculosis annually (1). In
Argentina, 11,503 cases of active tuberculosis and 910 deaths
were reported in 2017 (1). Nevertheless, it is well-known that
the majority of the subjects that were in contact withMtb do not
develop active disease, which might indicate that several factors,
such as host genetic, and environmental causes, would affect the
susceptibility to tuberculosis (2).
A successful immune response against Mtb depends on the
activation of CD4+T lymphocytes, especially Th1 cells (3, 4). In
fact, a reduced secretion of IFNG by T cells is a marker of the
severity of the disease. Consequently, patients with tuberculosis
(TB) displaying themost severe expression of the disease produce
the lowest amounts of IFNG against the pathogen (5, 6).
Moreover, we have reported that the IFNG rs1861494 single
nucleotide polymorphism (SNP) would act as a biomarker of
resistance to tuberculosis in the Argentinean population, since it
affects the secretion of IFNG (7). However, other cytokines might
be participating in the fight of the host against Mtb infection,
given that only IFNG is not enough to completely eliminate the
bacteria (8).
Several reports have proposed that the secretion of IL17A,
IL17F, and IL22 by Th17 cells contribute to the immune
response of the human host againstMtb (9). For example, IL17A
is produced by CD4+ T lymphocytes in order to eliminate
the primary infection, and to establish an effective memory
response (10–14). Recently, we found that IL17A augments
autophagy in Mtb-infected monocytes from individuals with
strong immunity to the bacterium; but this cytokine was unable
to increase autophagy levels in monocytes from TB with severe
disease, at least in part, because of a defect in the MAPK1/3
signaling pathway (15). However, when the amounts of IL17A
are too elevated they might be harmful for the host, leading
to an excess of neutrophils’ recruitment that might induce an
exacerbated inflammation and tissue damage (11). We also
reported thatMtb-Ag stimulated PBMCs fromTB secretedminor
levels of IFNG and greater amounts of IL17A as compared
to healthy donors (HD) (16). Moreover, we demonstrated that
CD4+IFNG+IL17A+cells from TB produce the highest levels of
IL17A, in direct correlation with the severity of the disease (16).
Finally, whereas we recently showed a positive association of the
IL17A rs2275913 SNP with protection against active tuberculosis,
we also demonstrated that IL17A rs2275913 SNP is related to
advanced disease in the Argentinean population (17).
IL17F is another important cytokine produced by the Th17
subset. Both IL17A and IL17F are members of the IL17 cytokine
family. In humans, their genes are located adjacent to one another
in the chromosome 6p12, they share 55% of sequence homology
and they have similar expression profiles (18, 19). IL17A and
IL17F can form either homodimers or heterodimers, and their
signaling is through a dimeric IL17RA and IL17RC receptor
complex (20). Functionally, both IL17A and IL17F participate in
the inflammation process by inducing the production of other
cytokines and chemokines, and the expression of antimicrobial
genes in fibroblasts, or endothelial cells (21). Strikingly, these
two similar cytokines may also have different, or even opposite,
functions in certain cases. For example, in the murine model
of experimental autoimmune encephalomyelitis (EAE), only
il17a−/− mice show a significant reduction in the severity of the
disease, indicating a role for IL17A but not for IL17F. In addition,
IL17A promotes inflammation in an asthma murine model, with
reduced infiltration of eosinophils in the airways of il17a−/−
mice. In contrast, il17f −/− animals show a greater infiltration
of Th2 cytokines and eosinophils, suggesting a suppressive
function of IL17F in asthma. It has also been demonstrated
that IL17A is protective while IL17F is harmful in certain types
of colitis (22, 23). Regarding the role of IL17A and IL17F
in the immunity against infections, these cytokines seem to
have redundant functions in the defense against Staphylococcus
aureus, although both cytokines are necessary in the control
of Citrobacter rodentium infection (22). Moreover, it has been
shown that patients with hyper-IgE syndrome, who have a
mutation in the STAT3 gene that leads to a defective IL17A/F
production, are highly susceptible to Staphylococcus aureus,
Streptococcus pneumonia, and Candida albicans infection (24).
Until now, there is limited information regarding the role
of IL17F during the human immune response against Mtb.
Accordingly, it has been reported that IL17F is produced by
whole blood stimulated with Mtb-Ag and by mucosal-associated
invariant T cells (MAIT) (25, 26). Furthermore, human and mice
deficient in RORGT, which show a significant decrease in the
lymphocyte production of IL17A and IL17F, display disseminated
infection by BCG and Mtb (27). In leprosy, IL17F plasma levels
are inversely proportional to the bacteriological index. However,
antigen-stimulated-PBMCs from leprosy patients with the most
severe form of the disease produced the highest amounts of IL17F
(28, 29). Overall, these findings suggest an important role for
IL17F in the immunity against mycobacteria.
The IL17F rs763780 SNP, a non-synonymous variant that
cause a His-to-Arg (H161R) substitution, is located in the third
exon of the IL17F gene, and was demonstrated to cause a loss in
the ability of IL17F to induce expression of certain cytokines and
chemokines (30). Moreover, it has been reported that the H161R
variant acts as a natural antagonist of the wild-type IL17F, because
it can bind to its receptor but without triggering a signal, blocking
the induction of IL8 expression (30, 31). Besides, several reports
have shown the association of the IL17F rs763780 SNP with
different inflammatory diseases, such as rheumatoid arthritis,
inflammatory bowel disease, asthma, Graves’ disease, ulcerative
colitis, cancer, among others (32–39). Until now, the association
between the rs763780 SNP and tuberculosis in the Argentinean
population has not been explored.
Given that IL17F induces chemokines and antimicrobial
peptides in the lung, and considering the cross regulation of
Th1 and Th17 responses during mycobacterial infections, we
hypothesized that IL17F participates in the human immune
response against Mtb. Therefore, in the present study, we used
an in vitro human model of primary cell cultures to assess the
production of IL17F byMtb-Ag-stimulated PBMCs fromHD and
TB. Moreover, we analyzed the association of the IL17F rs763780
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SNP with tuberculosis disease in Argentina, evaluating the
potential relationship of this polymorphism with immunological
and clinical parameters of the severity of the disease.
MATERIALS AND METHODS
Samples
Patients with active tuberculosis (TB) were diagnosed at the
Hospital Muñiz (Buenos Aires, Argentina), based on clinical
and radiological data, together with the identification of acid-
fast bacilli in sputum and isolation of Mtb in culture. Patients
recruited were individuals vaccinated with Bacille Calmette
Guerin Mycobacterium bovis (BCG), negative for HIV, with
no underlying diseases (cancer, diabetes, chronic obstructive
pulmonary disease, immune-related diseases, and others). In
addition, they had received <1 week of anti-tuberculosis therapy
at the time the sample was obtained. TB were classified as
High Responder (HR) patients (individuals displaying high
proliferative responses, IFNG production, and SLAM expression
in CD3+ cells againstMtb-Ag), and Low Responder (LR) patients
(subjects that exhibit low proliferative responses, IFNG secretion,
and percentages of SLAM+ CD3+ cells), as previously described
(6). Healthy donors (HD) recruited were individuals vaccinated
with BCG who lack history of tuberculosis, negative for HIV,
and with no underlying diseases (cancer, diabetes, immune-
related diseases, and others) or any pharmacological treatment
at the time of recruitment. All HD were tested using the
QuantiFERON-TB© Gold In-Tube test (QFT-Qiagen, Hilden,
Germany), and only QFT negative individuals were included in
this group. Subjects with latent tuberculosis (positive QFT) were
excluded from the study. All the individuals participating in this
study were over 18 years old.
All participants provided written, informed consent for the
collection of samples and subsequent analysis, in accordance with
the Declaration of Helsinki. The protocols conducted in this
work were approved by the Ethical Committee of the Dr. F. J.
Muñiz Hospital.
Antigen
In vitro stimulation of cells throughout the study was performed
with a cell lysate from the virulent M. tuberculosis H37Rv strain,
prepared by probe sonication (Mtb-Ag), and obtained through
BEI Resources, NIAID, NIH: Mycobacterium tuberculosis, Strain
H37Rv, Whole cell lysate, NR-14822 (Bethesda, MD, USA).
DNA Extraction, SNP Primers Design, and
Genotyping
Genomic DNA was extracted from whole blood samples
using the Quick-gDNATM Blood MiniPrep (ZymoReasearch,
California, USA) according to the manufacturer’s instructions.
DNA purity and final concentrations were determined
spectrophotometrically. Amplification refractory mutation
system-polymerase chain reaction (ARMS-PCR) was used for
the rs763780 SNP genotyping. The ARMS-PCR is based on
allele specific amplification of desired fragment using primers
corresponding to each allelic variant (40). Primer sequences were
designed by the Beacon Designer 7.2 software (Premier Biosoft
International, Ltd., CA, USA). The sequences of the primers
used were: Allele T specific forward 5′ GGATATGCACCTCTT
ACTGCACTT 3′, Allele C specific forward 5′ GGATATGCAC
CTCTTACTGCACTC 3′, Common reverse 5′ CACCAAGGC
TGCTCTGTTTCTT3′. As an internal control, Human Growth
Hormone (HGH) gene primers (Forward 5′ gccttcccaaccattccc
tta 3′, Reverse 5′ TCACGGATTTCTGTTGTGTTTC 3′) were
included in every PCRmix to verify successful amplification. The
amplification was performed in a Multigene Gradient thermal
cycler (LabNet International, NJ, USA). The conditions included
initial denaturation (94◦C for 5min) following a 35 time cycles
of denaturation at 94◦C for 30 s, annealing at 60◦C for 50 s,
and extension at 72◦C for 45 s each cycle; and final extension
at 72◦C for 5min. The rs763780 genotypes were assessed from
the presence/absence of PCR amplicon (106 bp), corresponding
to the specific allele (T/C) on 1.5% agarose gel stained with
SYBR Green. All genotypes of the rs763780 SNP were confirmed
by direct sequencing of the amplified IL17F gene fragment
by Sanger method (ABI 3130xl Genetic Analyzer, Applied
Biosystems, USA), and a 100% concordance was obtained among
the results obtained from ARMS-PCR and DNA sequencing
(Supplementary Figure S1).
Cell Preparation and Reagents
Peripheral blood mononuclear cells (PBMCs) were isolated by
centrifugation over Ficoll-Hypaque (Amersham Biosciences,
NJ, USA) and cultured (1 × 106 cells/mL), with or without
Mtb-Ag (10µg/mL) with RPMI 1,640 medium (Gibco,
MD, USA) supplemented with 1% L-glutamine, 1%
penicillin/streptomycin, and 10% human serum (Sigma-
Aldrich, MO, USA) during 5 days. Then, IL17F (RyD Systems),
IL17A (eBioscience), and IFNG (BioLegend) secretion was
measured in cell-free supernatants by ELISA, following the
manufacturers’ instructions.
Flow Cytometry
PBMCs were stimulated with Mtb-Ag for 4 (IL17F detection)
or 5 days (IL17A, IFNG, and SLAM detection), and incubated
with monensin (1 µl/ml; Sigma-Aldrich, MO, USA) for the
last 5 h of culture. Cells were then stained with specific
fluorophore-marked antibodies against CD3 (FITC, UCHT1,
BioLegend), CD4 (FITC, RPA-T4, BioLegend), and SLAM (PE,
A12, BD Pharmingen). Intracellular staining was performed
to determine IL17F (eFluor660, SHLR17, eBioscience), IL17A
(PE-Cy7, eBio64DEC17, eBioscience), and IFNG (APC, 4S.B3,
eBioscience) expression. For intracellular cytokine staining,
permeabilization buffer containing 0.5% saponin (Sigma-
Aldrich, MO, USA), and 10% fetal bovine serum (Gibco,
MD, USA) in PBS was used. Negative control samples were
incubated with irrelevant isotype-matched mAb in parallel with
experimental samples, which were analyzed on a FACSAria
II flow cytometer (BD Biosciences). To identify the different
cytokines produced by T lymphocytes, the gating strategy
comprised an initial determination of the blast lymphocytes area
according to their forward and side scatter properties, followed
by the discrimination of CD4+cells based on FITC fluorescence.
Finally, IL17F, IFNG, or IL17A+ cells were identified by staining
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with specific antibodies bound to the different fluorophores
(Supplementary Figure S2).
Proliferation Index
PBMC were stimulated with Mtb-Ag for 5 days and cells were
pulsed with [3H]TdR (1 µCi/well) and harvested 16 h later.
[3H]TdR incorporation was measured in a liquid scintillation
counter. Proliferation index for each individual was calculated as
cpm afterMtb-Ag stimulation/cpm after culturing with medium.
Statistical Analysis
The genotype and allele frequencies were obtained by direct
counting. Hardy-Weinberg (HW) equilibrium was tested
between cases and controls separately (Chi-Square goodness-
of-fit test). Comparisons of the distributions of the allele and
genotype frequencies between case and control were performed
using the Chi-Square test with Yates correction or Fisher exact
test. The level of association between the rs763780 genotypes
and the case/control condition was estimated as an odds ratio
(OR) with a 95% confidence interval (C.I.), calculated by
logistic regression after adjusting for confounding variables
(age/ethnicity/sex) (41). An a priori statistical analysis to
determine the final sample size was performed with an initial
population of 100 HD and 100 TB. The sample size estimation
to get a test power of 0.8, using the initial population HD minor
allele frequency (MAF) of 0.035 and the TB MAF of 0.095, was
of at least 164 individuals in each population. The quantitative
data were expressed as mean ± standard error of the mean
(SEM), and the Mann–Whitney U-test for unpaired and non-
parametric samples or the Wilcoxon W rank sum test for paired
and non-parametric samples were used to analyze differences
between groups. For categorical variables, the Chi-Square test for
homogeneity was performed to compare proportions of subjects
between groups and the Chi-Square goodness-of-fit test was used
to evaluate deviations from Hardy-Weinberg equilibrium. All
statistical analysis were performed using GraphPad Prism v6.0
(GraphPad Software, CA, USA) or the R software (42). p < 0.05
were considered statistically significant.
RESULTS
Demographic Characteristics of the
Population Studied
Demographic characteristics of HD and TB populations are
shown in Table 1. Both populations are comparable in terms of
ethnicity (p > 0.05) and age (p > 0.05), but displayed different
sex proportions (p < 0.001). Taking into consideration that the
differences in the proportions of sexes could affect the results of
genetic association studies, both populations under study were
stratified by sex, and the genotypic frequencies distribution of the
IL17F rs763780 SNP was calculated (Table 2). Given that we did
not find differences, we determined that the disparities between
the percentages of subjects from each sex would not impact in the
genotype distribution investigated in each population.




Age (Years) 33.6 ± 1.0 33.0 ± 1.0 0.103*
Ethnicity Caucasian 68.45% 64.07% 0.343X
American Indian 31.55% 35.93%
Sex Male 38.31% 73.00% <0.001X
Female 61.69% 27.00%
Categorical variables are expressed in percentages. Age value is expressed as Mean
± Standard Error of the Mean (SEM). Statistical differences were calculated using the
Mann-Whitney U-test for unpaired samples (*) and the Chi-Square (χ2 ) test for categorical
variables (X). n: number of individuals.
Bold numbers indicate statistically significant differences between groups, with a
p-value < 0.05.
TABLE 2 | Genotypic frequencies of the IL17F rs763780 SNP in HD and TB
populations stratified by sex.
rs763780 SNP genotypes HD (N = 201) TB (N = 200)
TT TC/CC TT TC/CC
Sex Male 65 12 102 44
Female 105 19 36 18
p-Value 0.991 0.674
p-Values were calculated by the Chi-Square (χ2 ) test for categorical variables. HD, healthy
donors; TB, tuberculosis patients.
The C Variant of the IL17F rs763780 SNP Is
Associated With Susceptibility to
Tuberculosis Disease
Genotyping of the rs763780 SNP in the populations of HD
and TB was performed by the ARMS-PCR technique as
described in Methods (Supplementary Figure S1). Remarkably,
no individual with the CC genotype was found in the HD
population, whereas three subjects carrying the CC genotype (out
of 200) were detected in the population of TB. For that reason,
all the statistical analyzes were performed in C carriers (TC+CC
genotypes), or non-C carriers (TT genotype).
Figure 1A shows the genotypic and allelic frequencies
distribution observed in HD and TB populations. Notably,
both populations were in Hardy-Weinberg (HW) equilibrium.
Chi-Square test of homogeneity determined that HD and TB
populations were significantly different regarding the genotypic
and allelic frequencies (p < 0.001, for genotypes and for
allele distribution). In fact, we detected a higher proportion of
individuals carrying the C variant of the SNP in TB patients as
compared to HD (TC+CC genotype: TB 30.50% vs. HD 15.42%,
p < 0.001). Moreover, we found a significantly higher proportion
of the C allele in the TB population (C allele: TB 16.00% vs.
HD 7.71%, p < 0.001). Odds ratios were calculated to estimate
the association level between the TC+CC genotype (C carriers)
and tuberculosis disease (Figure 1B) (41). When comparing
individuals carrying the C allele against non-C carriers, we
observed an odd ratio of 2.41 (95% C.I. = 1.36–4.36; p < 0.01),
indicating an association between C carriers and tuberculosis
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susceptibility in Argentina. Thus, these data demonstrate a
relationship between the C allele of the rs763780 SNP and
a higher frequency of individuals suffering from tuberculosis,
suggesting a role for IL17F in the development of the disease.
IL17F Production Is Higher in Individuals
With a More Effective Immune Response
Against Mtb
To further investigate the potential role of IL17F in tuberculosis,
we determined the production of this cytokine by PBMCs from
HD and TB. In order to optimize the detection of IL17F,
we initially performed a kinetic analysis. Thus, PBMCs from
HD were stimulated with Mtb-Ag and the production of this
cytokine was evaluated at 16, 48, and 120 h of culture. Our data
showed maximum IL17F production after 120 h (5 days) of Ag
stimulation (Supplementary Figure S3). Next, we analyzed the
ability of PBMCs from TB to secrete IL17F and compared it
to HD. Our findings showed that Mtb-Ag stimulation induced
significant IL17F production by PBMCs from TB (p < 0.001;
Figure 2A). Strikingly, and in sharp contrast with our reports
studying IL17A production, we detected higher levels of IL17F
in Mtb-Ag stimulated PBMCs from HD than in TB (p < 0.01;
Figure 2A), suggesting that these cytokines may play different
roles during tuberculosis disease (16, 17). Further validation
of the above data was obtained by flow cytometry analysis.
Accordingly, we were able to determine that CD4+ T cells
produced IL17F, observing the maximum differences in the
percentages of IL17F producing cells between HD and TB
after 4 days of Mtb-Ag stimulation (Supplementary Figure S4).
Furthermore, our data indicated that HD displayed significantly
higher numbers of CD4+IL17F+ lymphocytes as compared to TB
(p < 0.01, Figure 2B).
By using immunological parameters, we previously
differentiated two populations of TB in Argentina, High, and
Low Responders (HR and LR, respectively), where LR subjects
suffer the most advanced disease (6, 16, 43). In order to further
investigate whether subjects with a more effective immune
response against Mtb displayed higher IL17F production, we
analyzed the secretion of this cytokine by HR and LR TB. As
shown in Figure 2C, Mtb-Ag stimulated PBMCs from HR
secreted higher amounts of IL17F as compared to PBMCs from
LR (p< 0.05). It is important to note, the levels of IL17F detected
in HR were similar to the levels measured in HD (Figure 2A).
In line with the ELISA results, we found that the greatest
percentages of CD4+ T cells producing IL17F were observed in
Mtb-Ag stimulated PBMCs from HR (p < 0.05; Figures 2D,E).
Overall, these results indicate that individuals that mount a
more effective immune response against the bacterium secret the
highest amounts of IL17F, and suggest that IL17F might have a
protective role in human tuberculosis.
PBMCs From Individuals Carrying the C
Variant of the IL17F rs763780 SNP
Displayed a Reduced Immunological
Protection Against Mtb
To get additional evidence on the role of IL17F in tuberculosis,
we wondered whether individuals carrying the C variant of
the rs763780 SNP would display a weaker immune response
against Mtb. Thus, PBMCs from HD and TB, discriminated
in C carriers, or non-C carriers, were stimulated with Mtb-
Ag, and we evaluated IL17F, IFNG, and IL17A production,
proliferation index and SLAM expression (Figure 3). We found
no differences between IL17F levels produced by HD and
TB carrying the different SNP variants (Figure 3A). However,
considering that the C allele codifies for a non-synonymous
protein, individuals carrying the C allele could mount a different
immune response as compared to TT individuals. In fact, Mtb-
Ag stimulated PBMCs from HD carrying the C allele showed
significant lower production of IFNG and lower percentages
of CD4+ IFNG+ T cells as compared to TT HD (p < 0.05,
Figures 3B,F, Supplementary Figure S5). In the same way,Mtb-
Ag stimulated PBMCs from TB carrying the C allele showed
significant lower secretion of IFNG as compared to TT TB (p <
0.01, Figure 3B). Given the crucial role of IFNG in the protection
against Mtb infection (3–6), these results are in line with the
genetic association found between the C carriers of the rs763780
SNP and the susceptibility to tuberculosis.
We have previously demonstrated that IL17A production
correlates with disease severity in TB (16, 17). We found no
differences in the secretion of IL17A by HD carrying the different
variants of the IL17F rs763780 SNP (Figures 3C,G). In contrast,
we detected higher IL17A secretion and higher percentages of
CD4+ IL17A+ T cells in TB carrying the C allele, as compared
to TT TB (p < 0.05, Figures 3C,G, Supplementary Figure S5),
suggesting a relationship between this allele and the severity of
the disease. Furthermore, we observed that both the levels of
SLAM and the proliferation index were lower in HD carrying the
C allele (p < 0.05, Figures 3D,E), in line with our data showing
an association of this allele and the susceptibility to tuberculosis.
Besides, TC/CC TB displayed a significantly lower proliferation
index as compared to TT TB (p < 0.05, Figure 3D), in close
relationship with higher disease severity in TB carrying the C
allele. Overall, we showed that individuals carrying the C allele
of the IL17F rs763780 SNP displayed a weaker immune response
againstMtb, supporting a potential role for IL17F in tuberculosis.
The C Variant of the IL17F rs763780 SNP Is
Highly Represented in Patients With More
Severe Tuberculosis
Considering that PBMCs from TB carrying the C allele of
the rs763780 SNP secreted the lowest levels of IFNG and
the highest IL17A amounts against Mtb-Ag, and displayed the
lowest proliferation index, we next investigated whether this
polymorphism was related with the severity of the disease. Then,
we determined the genotypic and allelic distribution of the
rs763780 SNP in TB classified as HR and LR (6) (Figure 4).
We found that patients carrying the C variant were present in
higher frequency in the LR subpopulation of TB as compared
to HR (TC+CC genotype: LR 43.01% vs. HR 19.54%; p <
0.001). Also, we observed that the C allele was present in a
higher proportion in the subpopulation of patients with the most
severe tuberculosis (C allele: LR 23.12 vs. HR 9.77%; p < 0.001).
Thereby, our present findings demonstrate by genetic analysis
and immunological studies that TB carrying the C allele of
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FIGURE 1 | Genotypic and allelic frequencies of the IL17F rs763780 SNP in HD and TB populations in Argentina. (A) Pie chart representing the genotypic and allelic
distribution of the rs763780 SNP in healthy donor (HD, n = 201) and tuberculosis patient (TB, n = 200) populations. The number of individuals of each population and
the frequencies are detailed. Statistical differences were calculated using the Chi-Square (χ2) test of homogeneity. Both populations are in Hardy-Weinberg
equilibrium. (B) Odds ratio was calculated by logistic regression after adjusting for confounding variables (age/ethnicity/sex), in order to quantify the association
between tuberculosis and the different genotypes.
the IL17F rs763780 SNP display the weakest immune responses
againstMtb-Ag, and therefore they would be severely affected by
the disease.
TB Carrying the C Allele of the IL17F
rs763780 SNP Displayed the Highest Bacilli
Burden in Sputum Smear
Previously we showed that immunological attributes matched
clinical parameters studied in TB in Argentina (6, 16, 43). Thus,
we next decided to analyze whether there was a relationship
between clinical parameters commonly studied in tuberculosis
and the genetic variants of the rs763780 SNP. Table 3 shows
no significant differences in leukocyte, lymphocyte, monocyte,
or neutrophil numbers in peripheral blood of TB carrying the
different genotypes of the rs763780 SNP. Furthermore, we did not
find differences either in the radiological pulmonary lesions or in
the time of disease progression. However, when we analyzed the
genotype frequencies of the IL17F SNP according to the bacillary
load categories, we found significant differences among TC/CC
and TT carriers (BAAR−,+, ++, and +++; p < 0.05, Table 3). In
fact, when we examined the genotype frequencies comparing the
BAAR−, BAAR+, BAAR++, and BAAR+++ groups individually,
significant differences were detected between BAAR+ and
BAAR+++ (p < 0.01, significant after Bonferroni correction,
Table 3). Interestingly, TB carrying the TT genotype presented
the highest proportion of patients with low bacillary load (56.76%
BAAR+) and the lowest percentages of individuals with the
highest bacilli load (20.72% BAAR+++). In contrast, 40% of
patients carrying the C allele displayed themost elevated bacillary
load (BAAR+++), and a lower percentage of BAAR+ (28.89%).
In fact, when we performed a cumulative comparison of the
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FIGURE 2 | Production of IL17F by Mtb-Ag stimulated PBMCs from HD and TB. (A) Peripheral Blood Mononuclear Cells from healthy donors (HD, n = 21), and
tuberculosis patients (TB, n = 25) were cultured for 5 days either alone or with a lysate of Mtb (Mtb-Ag). Afterwards, IL17F production was determined in culture
supernatants by ELISA. (B) PBMCs from HD (n = 8) and TB (n = 8) were cultured for 4 days either alone or with Mtb-Ag, and IL17F production were determined by
Flow Cytometry. (C,D) TB were classified as High and Low Responder (HR and LR, respectively) individuals according to their immune response to Mtb-Ag. IL17F
production by stimulated PBMCs was determined by (C) ELISA and (D) Flow Cytometry. (E) Representative dot plots for each group (HD, HR TB, and LR TB) are
shown. IL17F secretion was determined by first gating on lymphocytes by light scatter, and then by gating on CD4+ T cells. Lines represent the Mean ± Standard
Error of the Mean (SEM). Statistical differences were calculated using the nonparametric Mann-Whitney U-test for unpaired samples (*p < 0.05 and **p < 0.01), and
the Wilcoxon W rank sum test for paired samples (#p < 0.05, ##p < 0.01, and ###p < 0.001).
genotype frequencies between patients with the lowest bacillary
load (BAAR− and +) and patients with the highest bacillary load
(BAAR++ and +++), significant differences were found (p <
0.01, Table 3). The majority of TB carrying the C allele showed
the highest bacillary load (BAAR++ and BAAR+++: 62.7%),
whereas a significant lower fraction of patients carrying the
TT phenotype displayed BAAR++ or BAAR+++ bacillary load
(39.34%). In contrast, the majority of TT TB presented the lowest
bacillary load (BAAR− or BAAR+: 60.66%), while the minority
of TB carrying the C allele displayed low bacillary load (37.25%).
Our findings would indicate that TB that carry the C allele of
the IL17F rs763780 SNP display weak cell-mediated immunity
against Mtb in association with higher bacilli load. Thus, taken
together, the present results suggest that the TC/CC genotype
of IL17F SNP might be related to the severity of the disease,
highlighting a role of this cytokine during active tuberculosis.
DISCUSSION
It is widely accepted that Th17 cells, that produce IL17A
and IL17F, contribute to the adaptive immunity to Mtb (9).
Nevertheless, while the contribution of IL17A to mycobacteria
immunity is usually accepted, the role of IL17F in tuberculosis
disease has been poorly studied to date. Therefore, in this study
we assessed the production of IL17F by Mtb-Ag-stimulated cells
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FIGURE 3 | Association between the IL17F rs763780 SNP genotypic variants and immunological parameters in tuberculosis. Peripheral Blood Mononuclear Cells
from healthy donors (HD) and tuberculosis patients (TB) carrying the different genotypes of the rs763780 SNP (TT and TC/CC) were stimulated for 5 days with a lysate
of Mtb (Mtb-Ag). Afterwards, IL17F, IFNG, and IL17A secretion were determined by ELISA (A–C, respectively). The proliferation index (cpm from stimulated cells/cpm
from un-stimulated cells) was evaluated by [3H] thymidine incorporation (D); and SLAM expression in CD3+ T cells was determinate by Flow Cytometry (E).
Additionally, CD4+ T cells production of IFNG (F) and IL17A (G) was determined by Flow Cytometry. Lines represent the Mean ± Standard Error of the Mean of the
increase in response to Mtb-Ag stimulation. Statistical differences were calculated using the non-parametric Mann-Whitney U-test for unpaired samples (*p < 0.05
and **p < 0.01).
from HD and TB. Moreover, we evaluated the relevance of the
IL17F rs763780 SNP during human infection caused byMtb.
We determined the production of IL17F using an in vitro
model of human primary cell cultures stimulated byMtb-Ag. Our
findings demonstrated that individuals that mount an effective
immune response against Mtb secreted the highest levels of
IL17F and showed the greatest percentages of CD4+IL17F+T
cells. Accordingly, whole blood stimulation with specific Mtb
antigens showed an increase in the production of IL17F in
individuals with latent tuberculosis infection (LTBI) as compared
to TB (25). Furthermore, uncontrolled infections with BCG
or Mtb were reported in individuals with defects in IL17A
and IL17F production (27). Besides, it has been also reported
that MAIT cells from TB produced higher levels of IL17F
at the site of infection than in the periphery (26).Thus, our
present findings, together with previous reports, suggest a
protective role for IL17F during the immune response of the host
against mycobacteria.
Unlike IL17A, which is mainly produced by T cells and
innate lymphoid cells, recent study shows that IL17F is secreted
by almost every cell populations, including myeloid-derived
cells and even organic epithelial or endothelial cells (44, 45).
Therefore, here we analyzed the secretion of IL17F by other
PBMCs populations besides CD4+. However, our results showed
very low percentages of CD14+ and CD8+ IL17F+ secreting
cells, with no significant differences between media and Mtb-
Ag condition (data not shown). Then, we hypothesize that
the contribution of IL17F secretion by PBMCs other than
CD4+ is minimal. Nevertheless, we cannot exclude the potential
contribution of IL17F production by other cell populations at the
site of the infection that were not analyzed in this study, so further
studies would be required to confirm our hypothesis.
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FIGURE 4 | Genotypic and allelic frequencies of the IL17F rs763780 SNP in HR and LR subpopulations of TB. Pie chart representing the genotypic and allelic
distribution of the rs763780 SNP in tuberculosis patients (TB, n = 180) classified as High and Low Responder (HR and LR, respectively) individuals according to their
immune response to Mtb-Ag. The number of individuals in each group and the frequencies are detailed. Statistical differences were calculated using the Chi-Square
(χ2) test of homogeneity.
The rs763780 SNP is located in the coding region (position
+7488) of the IL17F gene. It consists of a T→C substitution,
which generates a change in the amino acid sequence of IL17F
protein: from Histidine to Arginine in position 161 (H161R).
In vitro functional experiments demonstrated that the H161R
variant of IL17F lacks the ability to activate the mitogen-activated
protein kinase pathway, cytokine production, and chemokine
secretion in bronchial epithelial cells (30). Furthermore, the
H161R variant blocked the induction of the expression of IL8
by wild-type IL17F, acting as a natural antagonist of the cytokine
(30, 31). On the other hand, Puel et al. also performed in vitro
experiments with wild-type IL17F and the H161R variant (46).
Nevertheless, they stimulated a murine lung epithelial cells line
(MLE-12) and found that IL17F H161R variant induced the
secretion of keratinocyte-derived chemokine (an homologous of
human IL8) (46). Then, we believed that these discrepancies
could be related to differences in the experimental design (human
vs. murine cells). Besides, although human and murine IL17F
sequences (and the IL17RA/C sequences) share some degree
of similarity, they are not identical. These sequence differences
could explain why the functionality of the IL17F H161R variant
differs between human and mouse.
Several reports showed the association of this SNP with
different diseases, mostly inflammatory, such as rheumatoid
arthritis, inflammatory bowel disease, asthma, Graves’ disease,
ulcerative colitis and cancer, among others (32–39). In this
work, we analyzed the association of the C variant of the
rs763780 SNP with susceptibility to tuberculosis. Remarkably,
more than 85% of individuals from the HD population were
subjects exposed to Mtb but not infected with the pathogen
(negative QFT). These individuals were recruited from families
who had at least one patient living in the same household, having
high probability of repeated exposure, making this population
an appropriate control for the case-control study (47) and
emphasizing that these individuals would be efficiently resistant
toMtb infection. Importantly, only three TB expressing the IL17F
non-synonymous variant (CC genotype) were found, whereas
no HD carrying the CC genotype were detected. These findings
would suggest a role for IL17F in the development of the disease.
Ethnicity, sex and age differences between populations could
cause unauthentic relationships in genetic association analyses,
acting as confounding variables. In this work, we observed
that both populations under study (HD and TB) were similar
regarding age and ethnic composition. Notably, these ethnic
proportions were comparable to the ethnic composition of
the Argentinean population (48, 49). Although the HD and
TB populations evaluated presented different sex proportions,
we did not find discrepancies in the genotypic frequencies
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TABLE 3 | Association between the IL17F rs763780 SNP genotypic variants and
clinical parameters of tuberculosis severity.
TB population rs763780 SNP Genotypes p-Value
TT TC/CC
Hematologic studies (n = 123)
Leucocytes (cells/mL) 10 105 (± 449.6) 9 113 (± 540.4) 0.400*
Lymphocytes (cells/mL) 1 576 (± 71.70) 1 394 (± 115.3) 0.161*
Monocytes (cells/mL) 874.7 (± 46.81) 716.2 (±76.09) 0.092*
Neutrophils (cells/mL) 6810 (± 435.8) 7 423 (± 1 100) 0.759*
AFB in sputum smear (n = 173)
BAAR− 9.02% (n = 11) 11.76% (n = 6) 0.013X#
BAAR+ 51.64% (n = 63) 25.49% (n = 13)
BAAR++ 20.49% (n = 25) 27.45% (n = 14)
BAAR+++ 18.85% (n = 23) 35.30% (n = 18)
BAAR− or BAAR+
(Low bacillary 1+and negative)
60.66% (n = 74) 37.25% (n = 19) 0.007X
BAAR++ or BAAR+++
(High bacillary 2+and 3+)
39.34% (n = 48) 62.75% (n = 32)
Radiological lesions (n = 163)
Mild or Moderate 44.07% (n = 52) 40.00% (n = 18) 0.724X
Severe 55.93% (n = 66) 60.00% (n = 27)
Months of disease
progression (n = 118)
2.89 (± 0.28) 2.66 (±0.29) 0.848*
Hematologic studies representing the leukocyte, lymphocyte and monocyte counts in
peripheral blood are shown. Acid-Fast Bacilli (AFB) in sputum smear represent: BAAR−, 0
bacilli count; BAAR+, 1-9 bacilli/ 100 fields; BAAR++, 1–9 bacilli/ 10 fields; BAAR+++, 1–9
bacilli/ field. Radiological lesions: mild corresponds to patients with a single lobe involved
and without visible cavities; moderate relates to patients presenting unilateral involvement
of two or more lobes with cavities, if present, reaching a diameter no >4 cm; severe
corresponds to bilateral disease with massive affectation and multiple cavities. Clinical
symptoms analyzed in TB before hospital admission to establish the time (months) of
disease evolution were: weight loss, night sweats, symptoms of sickness or weakness,
persistent fever, presence of cough, history of shortness of breath, and hemoptysis.
Continuous data are expressed as Mean (± SEM), and categorical data are expressed as
percentages of genotype (n: number of individuals). Statistical differences were calculated
using the Mann-Whitney U-test for unpaired samples (*) and the Chi-Square (χ2 ) test for
categorical variables (X). # Individuals comparisons between AFB categories: p = 0.1058
for BAAR− vs. BAAR+; p = 1.0000 for BAAR− vs. BAAR++; p = 0.5750 for BAAR− vs.
BAAR+++; p = 0.0357 for BAAR+ vs. BAAR++; p = 0.0038 for BAAR+ vs. BAAR+++;
p = 0.5009 for BAAR++ vs. BAAR+++. Bonferroni correction for multiple comparisons:
α = 0.05/6 = 0.008.
Bold numbers indicate statistically significant differences between groups, with a p-
value < 0.05.
distribution of the IL17F rs763780 SNP in HD and TB stratified
by sex. Additionally, the genotypes distribution in the HD and
TB populations showed no deviation from HW equilibrium,
indicating that there is no population substructure. Furthermore,
the logistic regression used to evaluate the association between
the IL17F rs763780 SNP and tuberculosis disease was adjusted
for age, ethnicity and sex. In conclusion, we believe that it would
be improbable that the mentioned variables acted as confounding
variables in our genetic association analyses.
Even though other authors studied the relationship between
the rs763780 SNP and tuberculosis, variable results were reported
(50–55). We think that these inconsistencies might be associated
with ethnic variances, differences in the selection of the control
group and lack of HW equilibrium in the population analyzed,
among other causes. In contrast to our present findings, studies
conducted on Indian and Croatian populations found no
association between this polymorphism and tuberculosis (54, 55).
Nevertheless, our results are in agreement with studies performed
in Chinese and Iranian populations, where an association
between the SNP and the failure of anti-TB treatment was also
demonstrated, supporting the statement that subjects with the C
allele of the IL17F rs763780 SNP display a higher susceptibility to
tuberculosis disease (50–53).
No differences were found between IL17F secretion by PBMCs
from HD or TB carrying the different rs763780 SNP variants,
as expected for a SNP located in the coding region of the
gene. However, we detected that HD or TB carrying the non-
synonymous variant of the IL17F gene displayed the lowest IFNG
secretion. These results are in line with the genetic association
discovered between the C variant and the susceptibility to
tuberculosis, and suggest that the IL17F signaling pathway could
modify IFNG expression during human tuberculosis. Actually,
humans with altered production of IL17A, IL17F, and IL22,
in association with insufficient IFNG production, displayed a
defective control of Mtb (27). The transcription factor cAMP
response element binding protein (CREB) was reported to act as
a downstream signaling molecule for IL17F (56). Interestingly,
Samten et al. showed that CREB increased Mtb-Ag-stimulated
IFNG secretion by binding to the IFNG proximal promoter,
providing a link between the two cytokines (57).
Our results indicate that IL17A and IL17F may have different
roles in the context of tuberculosis. In fact, we previously
described that IL17A levels were higher in TB and correlated with
the severity of the disease whereas, in this work, we detected the
highest amount of IL17F inMtb-Ag-stimulated PBMCs fromHD
and HR TB (16). It is important to note that all the reagents that
were used in this study detect IL17F/F or IL17A/A homodimers.
It was recently reported that the IL17A/F heterodimer could
form two topologically-distinct heterotrimeric complexes, with
potentially different signaling properties (58). Thus, not only
IL17A and IL17F homodimers but also IL17A/F heterodimers
could participate in the immune response againstMtb.
We observed the maximum proportion of patients carrying
the C variant in the LR subpopulation, individuals that display
the most severe tuberculosis. We have previously reported
that HR patients had significantly higher percentages of total
lymphocytes and exhibited higher PPD diameters compared to
LR patients; and that LR individuals had severe pulmonary
lesions and a striking loss of weight compared to HR subjects
(6, 16, 43). Surprisingly, by evaluating clinical parameters usually
studied in tuberculosis, we did not find significant differences
in the radiological pulmonary lesions of the patients carrying
the different genotypes of the rs763780 SNP. Furthermore, we
found similar numbers of leukocyte, lymphocyte, monocyte, and
neutrophil counts in peripheral blood of TB. It is well-established
that Th17 cytokines are linked to neutrophil influx at the site of
infection (11, 59, 60). Thus, we believe that, to elucidate if TB
carrying the C allele showed increased neutrophil recruitment
to the site of infection, studies in bronchoalveolar lavages would
be required. On the other hand, we found that most of the
TB carrying the non-synonymous variant of the IL17F gene
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displayed the highest levels of IL17A and presented the highest
bacilli burden in sputum, in contrast to most of the TT TB. In line
with these results, we and other authors have reported that IL17A
directly correlates with high antigen load (17, 61). Moreover,
it was evidenced in leprosy that the bacteriological index was
inversely correlated with the IL17F levels found in plasma (28).
These findings indicate that TB carrying the C allele of the IL17F
rs763780 SNP exhibit a weak cell-mediated immunity against
Mtb-Ag, in direct association with elevated bacilli loads, which
demonstrate a higher severity of the disease.
We found an association between the IL17F rs763780 SNP and
different immunological and clinical parameters related to higher
susceptibility to tuberculosis and disease severity, emphasizing
the relationship between the SNP and the active form of the
infection. Although we could not rule out the possibility of a
non-causal association, like another functional polymorphism
in strong linkage disequilibrium with the rs763780 SNP, the
fact that the polymorphism under study is non-synonymic and
has been reported to act as a natural antagonist of the wild-
type IL17F (30, 31), makes it an excellent candidate for a
direct or causal association (62). Previously, we described that
the cytokine milieu plays a main role in the differentiation
of CD4+Th effectors cells (16, 63). In fact, for example,
we demonstrated that the addition of IL17A diminished the
levels of IFNG (63). One of our hypotheses associated to a
direct role of IL17F in TB, implies that different amounts of
this cytokine could influence the levels of IL17A and IFNG
secreted by HD and TB, affecting the onset of the infection.
In addition, another of our theories establishes that IL17F
could have an effect on several immunological parameters,
based on our previous reports showing that the amounts
of cytokines produced during Mtb infection can differentially
modulate the expression of co-stimulatory molecules (such
as SLAM), which in turn might regulate the responsiveness
of T cell to the pathogen (63–65). The factors mentioned
above, alone or in combination, may contribute directly
or indirectly to the genetic association found between the
C allele of the IL17F rs763780 SNP and the susceptibility
to tuberculosis.
Overall, we demonstrated that IL17F secreted by PBMCs in
the context of tuberculosis is produced in higher proportions
in individuals with an effective immune response against
Mtb. Also, by comparing the HD and the TB populations,
we found genetic evidences of an association between the
IL17F rs763780C allele, and susceptibility to tuberculosis.
These findings were further supported by in vitro analyses.
Additionally, we found genetic evidences of a direct relationship
between the C allele and the severity to tuberculosis, data
sustained by immunological and clinical parameters. Taken
together, our results identify the IL17F rs763780 SNP
as a biomarker of tuberculosis susceptibility and disease
severity in Argentina, and suggest that IL17F could play
a key role in the immune response of the human host to
Mtb infection.
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